Biotechnology
Soligenix Advances HyBryte Therapy for Cutaneous T-Cell Lymphoma Treatment
Soligenix is progressing its phase 3 clinical trial for HyBryte, a novel photodynamic therapy targeting early-stage cutaneous T-cell lymphoma, with potential to provide a noninvasive and precise treatment option for patients.
GeoVax Presents Promising Clinical Data for Gedeptin® Gene Therapy in Head and Neck Cancer Treatment
GeoVax Labs revealed clinical trial results for Gedeptin®, a novel gene-directed prodrug therapy showing potential in treating advanced head and neck cancers with minimal side effects and stability in patient outcomes.
Tevard Advances Promising tRNA Therapy for Duchenne Muscular Dystrophy
Tevard Biosciences reports breakthrough preclinical data demonstrating a novel suppressor tRNA therapy that successfully restored dystrophin protein and motor function in a Duchenne muscular dystrophy model, potentially offering hope for patients with nonsense mutations.
Lexaria Secures $2 Million in Direct Stock Offering Amid Challenging Market Conditions
Lexaria Bioscience has successfully closed a registered direct offering of 2 million shares at $1 per share, raising $2 million for working capital and corporate purposes without significant shareholder dilution.
Creative Biolabs Advances Antibody-Drug Conjugate Technology with Innovative Engineering Techniques
Creative Biolabs has made significant breakthroughs in antibody-drug conjugate (ADC) development, demonstrating advanced glycosylation engineering and innovative approaches to targeting cancer treatments through bispecific and antibody-oligonucleotide conjugates.
Sino Biological Expands North American Infrastructure to Mitigate Global Trade Uncertainty
Biotechnology company Sino Biological has strategically positioned its operations across North America to ensure uninterrupted product and service delivery amid complex global trade dynamics, demonstrating proactive business resilience.
Quantumzyme Develops Green Chemistry Process for Sustainable Ibuprofen Production
Biotechnology company Quantumzyme has developed an enzymatic process for producing ibuprofen that significantly reduces environmental impact and manufacturing costs through innovative green chemistry techniques.
Calidi Biotherapeutics Advances Cancer Treatment Platform with Innovative Immunotherapy Approach
Calidi Biotherapeutics has developed a novel systemic antitumor virotherapy platform that delivers an IL15 superagonist directly into tumor microenvironments, potentially revolutionizing metastatic cancer treatment by boosting immune response while minimizing systemic toxicity.
Calidi Biotherapeutics Names New CEO, Grants Significant Stock Option Package
Calidi Biotherapeutics has appointed Eric Poma as its new CEO and granted him a substantial stock option package, signaling potential strategic shifts in the clinical-stage biotechnology company's leadership and future direction.
Creative Biolabs Advances CIK Cell Therapy Development for Cancer Treatment
Creative Biolabs offers comprehensive solutions for cytokine-induced killer (CIK) cell therapy development, potentially accelerating cancer immunotherapy research through advanced cellular isolation, expansion, and characterization techniques.
Stem Cell Therapy: A Promising Frontier in Blood Cancer Treatment
Advancements in stem cell therapy offer hope for patients battling blood cancers like leukemia, myeloma, and lymphoma, with ongoing research exploring innovative treatment options.
Kairos Pharma Receives DoD Grant to Advance Lung Cancer Biomarker Research
Kairos Pharma secures a Department of Defense grant to support its innovative cancer research, focusing on developing ENV105, a potential breakthrough in addressing drug resistance in prostate and lung cancers.
Helix BioPharma Strengthens Leadership with Strategic Executive Appointments
Helix BioPharma has appointed Veronika Kandziora as Chief Operating Officer and Dr. Jessica Kourniaktis as Director of Communications, signaling a strategic move to accelerate growth and enhance communication in its mission to develop innovative cancer treatments.
Kairos Pharma Secures Department of Defense Grant for Lung Cancer Biomarker Research
Kairos Pharma has received a Department of Defense grant to advance research on lung cancer biomarkers, furthering its innovative approach to targeting drug resistance in cancer treatments. The company is progressing clinical trials for its lead candidates ENV105 and KROS101 with promising potential in oncology.
Silexion Therapeutics Partners with Catalent to Advance Breakthrough KRAS Cancer Treatment
Silexion Therapeutics is collaborating with Catalent to develop SIL204, an innovative RNA interference therapy targeting multiple KRAS mutations in pancreatic cancer, with potential to transform treatment paradigms in a $470 billion precision medicine market.
Calidi Biotherapeutics Taps Eric Poma as New CEO to Drive Clinical Growth Strategy
Biotech firm Calidi Biotherapeutics has appointed Eric Poma as its new CEO, signaling a strategic leadership transition aimed at advancing its cancer-targeting stem cell-based virotherapy platform into later-stage clinical development.
Ohio State Researchers Uncover Potential Breakthrough in Glioblastoma Treatment
Scientists have identified a key enzyme, PGM3, that could be crucial in developing more effective treatments for glioblastoma, one of the deadliest forms of brain cancer by targeting a critical growth pathway.
Quantumzyme Develops Sustainable Enzymatic Method for Ibuprofen Production
Biotechnology company Quantumzyme is set to publish a patent for an innovative enzymatic approach to manufacturing ibuprofen, offering a more environmentally friendly and efficient pharmaceutical production method.
GeoVax Set to Disclose Q1 2025 Financial Results and Provide Corporate Update
Clinical-stage biotechnology company GeoVax Labs will release its first quarter 2025 financial results and host a conference call, offering insights into its COVID-19 vaccine development and oncology programs. The announcement provides stakeholders an opportunity to learn about the company's recent progress and strategic direction.
Calidi Biotherapeutics to Showcase Innovative Cancer Immunotherapy Platform at Investor Webinar
Calidi Biotherapeutics will host an investor webinar highlighting its stem cell-based delivery platforms for oncolytic virus therapies, featuring updates on promising cancer treatment programs designed to enhance immune system response.
GeoVax Bolsters Technical Development with Experienced Biologics Executive
GeoVax Labs has appointed Dr. Senthil Ranganathan as Vice President of Technical Development and CMC Operations, signaling a strategic move to enhance the company's biologics development capabilities and advance its clinical-stage vaccine and immunotherapy portfolio.
Creative Biolabs Advances Antibody Technologies to Revolutionize Cancer Treatment
Creative Biolabs is expanding its innovative antibody-related technologies, targeting critical advancements in cancer research and immunotherapy. The company's platforms aim to enhance drug delivery precision and improve therapeutic strategies for previously challenging medical conditions.
Creative Biolabs Advances Drug Delivery with Custom Emulsion Technology
Creative Biolabs has developed innovative emulsion formulations designed to enhance drug stability and bioavailability, offering customized solutions for challenging pharmaceutical delivery systems. The breakthrough technology addresses critical drug solubility issues across various pharmaceutical applications.
Creative Biolabs Expands Induced Pluripotent Stem Cell Research Services
Creative Biolabs introduces comprehensive induced pluripotent stem cell (iPSC) services, offering researchers advanced tools to accelerate stem cell therapy research and development across multiple disease domains.
Mayo Clinic Researcher to Present Findings on Aditxt's ADI-100™ Preclinical Study
Aditxt Inc. will host a May 2 update featuring Mayo Clinic's Dr. Charles Howe discussing key findings from a preclinical study of ADI-100™, offering insights into the company's immune modulation therapy research.
Calidi Biotherapeutics Receives FDA Clearance for Innovative Cancer Treatment Trial
Biotech firm Calidi Biotherapeutics has obtained FDA approval to begin clinical trials of CLD-201, a novel stem cell-based virotherapy targeting solid tumors. The therapeutic approach combines adipose-derived stem cells with oncolytic vaccinia virus, potentially offering a breakthrough in treating challenging cancer types.
Global Brain Tumor Treatment Market Projected to Reach $7.15 Billion by 2035
The brain tumor treatment market is expected to experience substantial growth, driven by advances in medical technologies like immunotherapy and personalized medicine. The market's projected 7.2% compound annual growth rate signals significant potential for medical innovation and investment.
ProPhase Labs Sells Subsidiaries for $23.6M, Streamlines Business Focus
ProPhase Labs has completed the sale of its Pharmaloz subsidiaries to a private equity group, eliminating over $20 million in debt and positioning the company to concentrate on its core biotech and diagnostics businesses.
Utah's Life Sciences Showcase at State Capitol Highlights $22B Industry Growth
Utah's burgeoning life sciences sector, representing $22 billion in GDP and employing 180,000 residents, will demonstrate its economic impact and healthcare innovations to state legislators at the annual Life Sciences Day on the Hill event.
Life Science Investment Leader Michael Ryan Joins Sigyn Therapeutics Board Amid Blood Purification Tech Development
The appointment of Michael Ryan, founder of Ireland's largest angel investment syndicate, to Sigyn Therapeutics' Board of Directors strengthens the company's position in developing crucial blood purification technologies for treating life-threatening conditions.